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As oral chemotherapy agents are increasingly developed and used, pharmacotherapy in 
oncology care is shifting from intravenous formulations administered under the close and 
watchful eye of clinicians to therapies that are self-administered in the privacy of a patient’s 
home. 1 With this shift comes the need for oncologists to assess and support medication 
adherence, in addition to managing treatment toxicities. 2 National practice standards and 
guidelines have been published in an effort to aid oncology practices in the safe administration 
and management of oral chemotherapy.3,4 Despite the known importance of medication 
counseling to patient adherence and safe medication practices, medical record documentation is 
known to be incomplete for medication counseling,5 and little is known about how oncologists 
address medication counseling during routine office visits.     
Medication adherence is the process by which patients take their medications as 
prescribed, including whether a patient initiates taking the medication, how they implement 
taking the medication, and whether they discontinue taking the medication.6 Recent studies have 
revealed adherence to oral chemotherapies to be highly variable— ranging from as low as 23% 
to as high as 97%.7 Several factors have been associated with non-adherence, including adverse 
side effects, concomitant drug burden, and low social support.8 Many cancer hospitals and other 
oncology care providers have developed interventions that specifically target those receiving oral 
chemotherapy treatment.9 Studies of these interventions have highlighted their inconsistent 
ability to enhance patients’ medication adherence as well as challenges accompanying attempts 
to support self-administered cancer therapy.10,11 Although a recent systematic review illustrated 




medication adherence12, the poor quality of those studies reviewed, and those included in other 
similar reviews10,11, simultaneously highlight ongoing gaps in knowledge. 
Oral chemotherapy is unique in its frequent use of repeated treatment-rest cycles, 
concerns regarding toxicity, evidence of overuse, and need for ongoing symptom monitoring— 
all of which make counseling needs complex. Capecitabine is no exception. An oral 
chemotherapy agent that is dosed based on a patient’s weight and height, capecitabine is similar 
to other oral chemotherapies in it is taken twice daily on a schedule of two weeks on and one 
week off,13 and has been reported to be both under- and over-used by patients.14–22    
Despite the often involvement of multiple clinicians in the oncology setting, oncology 
patients report physicians as their primary source of information regarding chemotherapy.23  
Importantly, a recent study found oncology patients who reported a high satisfaction with the 
information they received regarding the impact of their therapy were more adherent.8 Such 
finding is consistent with that from other clinical contexts where patient-physician 
communication repeatedly has been found to be associated with patients’ adherence to prescribed 
medications. 24,25 Despite the likely importance of oncologist communications to oral 
chemotherapy adherence, to our knowledge, no prior study has used observation of oncologist-
patient office visit conversations to understand how oncologists assess and support patient 
adherence to oral chemotherapy.   
Using audio-recordings for patients with colorectal cancer identified from the Verilogue 
Point of Practice database (http://www.verilogue.com), we describe patient-oncologist office-
based discussions of oral chemotherapy treatment. Of particular interest was the extent to which 




and side effects) and offer strategies for managing medication side effects. We also describe how 
oncologists assess their patient’s adherence to prescribed oral chemotherapy.  
 
Methods 
Study Population and Data Source 
The Verilogue Point-of-Practice database is described in detail elsewhere.26–29 In brief, 
Verilogue staff identify and recruit physicians from diverse practices and specialties to develop 
the Point-of-Practice database. Only patients who consent to having their encounter audio-
recorded are included in the database.   
For this study, Verilogue staff identified 25 outpatient encounters with a medical 
oncologist in the United States between January 1, 2014 and December 31, 2017 for which the 
patient: 1) was aged 19 years or older, 2) was diagnosed with colorectal cancer, and 3) had 
capecitabine listed as a current treatment. In addition to audio-recordings and transcripts, the 
Verilogue database contains structured information on the patient’s gender, race, age, and current 
chemotherapy medications as well as the treating oncologist’s gender and years in practice. The 
Institutional Review Board (IRB) at the University of North Carolina at Chapel Hill approved 
this study as exempt. 
Qualitative Content Analysis 
Using Qualtrics software 30, we developed a structured coding worksheet to identify and 
describe the medication counseling content present in patient-oncologist office visit discussions. 
To develop the coding items, we initially used results from a scoping review we are completing 
to determine the content of patient-clinician communication previously evaluated for its 




the assessment and management of side effects, financial access assistance, logistical assistance 
accessing the medication, and concurrent medication management. In addition, to capture the 
comprehensiveness of the medication information provided by the oncologist, we used the 
Medication Communication Index (MCI).31 The MCI includes items for the clinician’s provision 
of medication name, purpose or justification, duration, adverse effects, and dosage. Finally, for 
medication adherence assessment, we considered the conceptual framework proposed by Vrijens 
and colleagues to code both therapy continuation and implementation.6 An assessment of 
continuation was captured if the oncologist asked the patient about his/her continued use of 
capecitabine or willingness to complete a subsequent treatment cycle(s). Implementation 
assessments were recorded if the oncologist asked the patient or the patient volunteered 
information about missed doses, doses taken per day, or modifications to their medication taking 
behavior. We also included an item to capture whether or not the oncologist, patient, or both 
mentioned the availability of a separate program or staff member available to provide medication 
assistance or support. A number of these codes are consistent with the American Society of 
Clinical Oncology (ASCO) Quality Oncology Practice Initiative (QOPI) Certification Program 
Standards (e.g., evaluation of treatment-related toxicities and patient adherence when 
chemotherapy is administered outside the healthcare setting).3 In addition to using these a priori 
determined components of medication counseling, research team members iteratively read and 
identified themes from batches of two office visit transcripts independently, and then met to 
discuss identified themes. Using this approach, we developed codes to capture details regarding 
the content of side effect management discussions. For example, we developed items specific to 
each body system that captured whether or not a side effect was discussed and/or endorsed as 




were discussed. We also developed a code for the discussion of treatment phase (i.e., pre-
treatment initiation, mid-treatment course or post-treatment), and concomitant infused 
chemotherapy use. Each item was coded as having occurred regardless of who initially raised the 
topic.  
Coding was completed in rounds, with two coders (B.N. and B.W.) iteratively coding five 
transcripts independently and then meeting to discuss results. Within each round, coders 
reviewed two of the same transcripts. A separate lab member calculated interrater reliability 
scores for the double-coded transcripts (n=5).32 Cohen’s kappa was calculable for 24 items. For 
items where Cohen’s kappa statistic was <0.55 (n=4), we re-coded the items using consensus 
coding. For the other items, the kappa score ranged from 0.55 – 1.00 (mean 0.87). For additional 
items (n=19) for which insufficient variability existed in the coded responses for a Cohen’s 




Twenty-four encounters were included in the analyses. One encounter was with a patient 
who had completed capecitabine therapy and was therefore excluded. The demographic and 
clinical characteristics of the patient sample are presented in Table 1. Patients were seen by 
seventeen different oncologists who were primarily male (n=15) and practicing between 3 and 10 
years (n=11). Office visit recordings ranged in length from 3-35 minutes, averaging 14 minutes 






Medication Information  
All visits included the word “capecitabine” or its brand name. All visits also included a 
discussion of associated side effects. Over the course of a visit, patients who had not initiated 
therapy were generally provided the recommended basic elements of medication information 
(e.g., medication name, dosing frequency, therapy duration, number of tablets per dose, and 
adverse effects). Conversely, office visit discussions for patients in the midst of their treatment 
course contained less of this information. For example, patients who were mid-course were often 
not reminded of the purpose of the medication or the planned duration of therapy. Nor were they 
commonly counseled on either the prescribed frequency of medication administration or the 
number of tablets to take for each dose.  
Therapy Continuation and Implementation 
All patients who had initiated capecitabine were assessed for their continued use of the 
medication. Most encounters included a brief assessment only such as: 
 
Oncologist: So you continue taking [capecitabine] by mouth?  
Patient: That is correct.  
       Case 541, mid-treatment  
 
On the other hand, oncologists’ assessments of therapy implementation (e.g., missed 
doses) among patients who had initiated therapy was more sporadic, and when such discussions 
occurred, they varied in scope. These discussions ranged from simple, seemingly incidental 
statements from the patient that a dose had been missed to in-depth assessments initiated by the 
oncologist that specifically asked about medication taking behavior. The quotes below illustrate 
such variability.  
Oncologist: Okay. And let’s go ahead. This will be cycle number four. Okay, let’s see 







Patient: Yeah, I missed a day in, uh, because they made, well they called, I ordered it 
on Thursday. [INAUDIBLE] Tuesday. 
        Case 43322, mid-treatment 
 
Oncologist: And you’re taking, um, three in the morning and three in the evening? 
Patient: Yes.  
Oncologist: Okay So it’s been seven days already and when will you finish? See it 
over there? [DATE] so Tuesday, last Tuesday is when you started? 
Patient: Yes. 
Oncologist: So it’s going to be probably [DATE] will be, the, [DATE] will be the last 
one, right? That’s what I’m thinking. 
       Case 61386, mid-treatment  
 
Side effect Management 
At least one side effect was discussed in all encounters, commonly gastrointestinal (GI) 
system-related side effects. Encounters with patients who had yet to initiate treatment discussed 
common side effects reported with capecitabine and included a discussion of self-management 
strategies to try should the patient become symptomatic. Once therapy had been initiated, 
discussion of self-management strategies in absence of symptom presentation was rare. Instead, 
once therapy had been initiated side effect self-management strategies were offered in a reactive 
fashion (i.e., only when the patient endorsed having the side effect). For example, one patient 
was provided with the following suggestion: 
Patient: My tongue on both sides was sore like I’d bitten it, but I hadn’t.  
Oncologist: Have you ever tried some saltwater with… bicarbonate and just swishing 
it around and spitting it out?  
       Case 19249, mid-treatment  
 
Concurrent Medication Management  
Patients’ use of concurrent oral medications were also discussed. These discussions 
typically focused on patients’ use of medications for the management of capecitabine’s side 




comorbid condition was rare. The following quote illustrates a typical discussion of concurrent 
medications: 
Patient: I’m doing good. 
Oncologist: Any problems? 
Patient: Well, I’ve been nauseous. 
Oncologist: A little bit of nausea. Are you taking your [prochlorperazine]?  
Patient: Yes, I need to get a refill on it, too. 
       Case 1207, mid-treatment  
 
Medication Access 
Discussions regarding how medications would be obtained and other logistical 
assessments were common. These types of assessments were directed primarily at the oncologist 
trying to understand when the medication would be in the patient’s possession. For example, 
oncologists often coordinated subsequent visits based on the patient’s access to capecitabine. For 
example:  
Oncologist: “… how many days does it take for the pharmacy to deliver the 
medicine?” 
Patient: “Um, a couple of days.”  
Oncologist: “Yeah. That’s fine?”  
Patient: Yeah. That’s a couple of days.  
Oncologist: “Okay, so why don’t we get together that Monday. Um, we’ll just make 
sure everything is fine and then order the next [cycle].” 
       Case 62823, mid-treatment  
In four office visits, we observed an oncologist inquiring about the patient’s financial access to 
capecitabine: three encounters with patients who had yet to initiate therapy and once with a 
patient mid-course.  
References to Other Available Programs and/or Clinician Support  
No encounter contained a discussion of another medication support program or other 
clinician that might be available to the patient or their caregiver(s) to assist with medication 






Patient medication adherence is a common and costly challenge that is relatively new 
within the context of oncology care.33 Using audio-recordings from a national sample of 
oncology office visits, we identified the content of and gaps in routine medication counseling 
received by patients with colorectal cancer prescribed capecitabine. We found that although 
virtually all patients discussed continuation of their oral chemotherapy with their oncologist, 
discussions addressing whether patients were taking their chemotherapy as prescribed were less 
commonplace. Likewise, while we found all office visits included discussion of the common side 
effects to therapy, discussion of self-management strategies patients could employ were more 
varied, and rarely provided pre-emptively once therapy was initiated. Instead, once a patient 
initiated therapy, self-management strategies seemed to be provided to patients only after they 
presented with a side effect.  
 Our findings illustrate that oncologists commonly engage in medication counseling with 
their patients prescribed capecitabine. Yet, the counseling we observed was often void of 
recommended best practices. For example, oncologists often did not directly ask patients about 
their therapy implementation (e.g. whether they missed, skipped, or cut doses). By not asking 
about therapy implementation, oncologists place the responsibility of reporting non-adherence on 
the patient. Because patients may not understand the importance of disclosing medication 
adherence behaviors and/or be comfortable divulging challenges with medication adherence, 
oncologists who do not inquire about a patient’s medication taking behaviors before making 
treatment changes may be making dose adjustments and other decisions based on erroneous or 
incomplete information. In the oncology setting where medication overuse and underuse are 




treatment toxicities as well as avoidable disease progression or even premature death. Standards 
put forth by ASCO and others3,4, clearly advocate for the periodic assessment of not only 
whether or not a patient continues to take their prescribed medication, but how they are taking it. 
As evidenced by commonly used medication counseling strategies, such discussions should 
include periodic assessments of the barriers patients may face in taking prescribed medications 
as directed.10    
 While oncologists consistently inquired about the presence of side effects, they often do 
not provide patients with a self-management strategy before the patient presents with a symptom. 
Such an omission is increasingly costly not only to the wellbeing of patients, but also to 
organizations responsible for delivering their care as studies have repeatedly found side effects to 
be a contributing factor in costly visits to the emergency department among cancer patients being 
treated with chemotherapy.35–37 In addition to adhering to national quality standards, oncology 
practices may implement specific protocols for building knowledge in the patients’ ability to not 
only take their prescribed chemotherapy properly, but also identifying and managing its 
associated side effects before they progress in severity. This presents an opportunity to utilize 
other members of the healthcare team, such as pharmacists, in the patient’s oncologic care. Some 
pharmacist-led interventions have previously shown success in the early detection of side effects 
and subsequently lower hospitalizations.38–41 
To our knowledge, our study is the first to use office visit audio-recordings to evaluate 
patient-oncologist medication counseling discussions within oncology care. Despite the 
advantages of such observational data from an existing database of national scope, its use 
introduces a number of limitations. First, although visits were drawn from a national sample, 




representative of oncologist medication counseling more broadly. Compounding this is our 
inability to describe either the patient or oncologist sample in more detail. As such, we are not 
able to provide additional contextual information regarding either patients’ clinical (e.g., where 
within a treatment course patients were or their prescribed dosing) or social (e.g., educational 
attainment or health literacy) characteristics. In addition, because oncology care usually is 
provided by clinical teams that include advanced practitioners and pharmacists, by focusing 
solely on patient-oncologist discussions we may miss important medication counseling delivered 
by others. As such, we cannot draw conclusions regarding all medication counseling received by 
oncology patients, but only that provided by an oncologist during office visits. Nonetheless, the 
counseling received during such visits seems particularly relevant both because of the 
importance patients place on this as an information source23, and because of the need for 
physicians to understand patient medication adherence before altering therapy. Future 
longitudinal studies focusing on medication counseling delivered by other members of the 
oncology care team are needed to provide further insight into these issues. Of note, however, is 
the fact that no patient-oncologist discussion mentioned a medication support program or other 
clinician available to assist the patient with their medications. In addition, although the 
importance of patient-physician office visit communication to patient outcomes in other clinical 
contexts has been shown24,25, a limitation of the current study is the inability to link identified 
communication behaviors with patient adherence and other outcomes.   
 Using audio-recordings from a national sample of patient-oncologist office visits, we 
identified a number of potentially important opportunities to enhance oncologists’ medication 
counseling. Among these is the opportunity for oncologists to assess how patients are taking 




they present with symptom burden. As reliance on oral cancer treatment expands, it is 
increasingly important to understand how patient-oncologist office visit discussions can best 
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Table 1. Patient Sample Characteristics (N=24) 
Age 
     19-34 1 (4%) 
     35-54 7 (29%) 
     55-74 10 (42%) 
     75+ 6 (25%) 
Sex 
     Male 9 (38%) 
     Female 15 (62%) 
Race 
     White 19 (79%) 
     Other 5 (21%) 
Treatment Status 
     Pre-treatment Initiation 5 (21%) 
     Mid-treatment  18 (75%) 
     Unknown 1 (4%) 
Concomitant Infusions 
     Bevacizumab 2 (8%) 
     Fluorouracil 1 (4%) 
     Irinotecan 1 (4%) 
     Oxaliplatin 10 (42%) 
     None  11 (46%) 
Caregiver  
     Present 12 (50%) 
 
